proton pump inhibitor refractory gastroesophageal reflux disease mosapride
Conditions
Interventions
omeprazole 20 mg once daily plus mosapride 5 mg thrice daily for 4 weeks ,omeprazole 20 mg once daily plus placebo thrice daily for 4 weeks
Experimental Drug,Active Comparator Drug
omeprazole plus mosapride combination therapy,omeprazole monotherapy
Sponsors
Rajavithi Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: the patients who experienced a symptom of heartburn and/or regurgitation more than twice weekly unresponsive to at least 8 weeks of a standard dose of proton pump inhibitor, defined by having the frequency scale for symptoms of gastroesophageal reflux disease total score of eight points or more
Exclusion criteria
Exclusion criteria: (i) who had a previous history of esophageal or gastrointestinal surgery except appendectomy and cholecystectomy (ii) who had severe cardiac or pulmonary disease, renal failure, liver cirrhosis and severe systemic illness (iii) who had an active Helicobacter pylori infection, determined by both the rapid urease test and histological identiï¬cation, or upper gastrointestinal diseases such as malignancy or peptic ulcers (iv) who was in a state of pregnancy or lactating woman (v) who were hypersensitivity or allergy to mosapride or omeprazole
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gastroesophageal reflux symptom relief at the end of the intervention the frequency scale for symptoms of gastroesophageal reflux disease | — |
Secondary
| Measure | Time frame |
|---|---|
| number of symptoms free day within 4 weeks of the study period patient reported outcome using a diary book | — |
Countries
Thailand
Contacts
Public ContactApichet Sirinawasatien
Rajavithi Hospital
Outcome results
None listed